Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.

Ther Clin Risk Manag · 2009 · PMC2697512 · PMID 19436606

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

did not reach statistical significancep = 0.13not close (p > 0.1)

TTP in the early relapse cohort also suggested improvement with combination therapy (205 vs 276 days), but did not reach statistical significance (p = 0.13, HR = 0.94).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.